Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 5/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166637 | 0.88 | MAPT (0.44) | MAPTGAANPC1HTTRAB9A | |
| SCHEMBL3172504 | 0.86 | MAPT (0.43) | MAPTGAANPC1HTTRAB9A | |
| SCHEMBL425233 | 0.81 | HTT (0.65) | MAPTNPC1HTTRAB9AKMT2A | |
| SCHEMBL3174614 | 0.80 | CDC7 (0.48) | MAPTGAANPC1HTTRAB9A | |
| SCHEMBL13393641 | 0.78 | MAPT (0.40) | MAPTGAANPC1HTTRAB9A | |
| SCHEMBL13392948 | 0.77 | POLB (0.43) | MAPTGAANPC1HTTRAB9A | |
| SCHEMBL13392958 | 0.75 | HPGD (0.41) | MAPTGAANPC1RAB9AKMT2A | |
| SCHEMBL13392955 | 0.75 | APOBEC3G (0.51) | MAPTGAANPC1RAB9AKMT2A | |
| SCHEMBL13393640 | 0.75 | MAPT (0.38) | MAPTGAANPC1HTTRAB9A | |
| SCHEMBL1720715 | 0.73 | ALDH1A1 (0.51) | MAPTGAANPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7645881-B2 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | PTC THERAPEUTICS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1781289-A1 | THIENOPYRIDINES FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006019832-A1 | THIENOPYRIDINES FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060019976-A1 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | PTC THERAPEUTICS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | MAPT 4291/4885GAA 140/4885NPC1 291/4885 |
| US-20060019976-A1 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | DIMT1, EIF2AK2, ELL | MAPT 3978/4885GAA 2018/4885NPC1 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.